Memantine: An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer\u27s disease

Memantine (Namenda, Forest) is the newest medication to receive FDA approval for the treatment of Alzheimer\u27s disease and the first to be approved with a moderate-to-severe indication. All previously approved Alzheimer\u27s disease treatments belong to the cholinesterase inhibitor class and are approved with a mild-to-moderate indication. Memantine has been used for more than 10 years in Germany and features a novel mechanism of action: N-methyl-D-aspartate (NMDA) antagonism. It has been shown to be effective in double-blind, placebo-controlled trials as monotherapy and in combination therapy with the cholinesterase inhibitor donepezil in patients with moderate-to-severe Alzheimer\u27s disease. Memantine has also shown positive treatment effects in patients with vascular dementia. It has a favorable adverse effect profile with no adverse effect occurring at more than twice the rate of placebo. The availability of memantine will give clinicians and caregivers a new safe and effective treatment option for Alzheimer\u27s disease. Forest Laboratories has filed an sNDA seeking a mild-to-moderate Alzheimer\u27s disease indication for memantine as monotherapy